Generics news from FiercePharma
NewsPharma outsourcing continues to swell
Outsourcing is still on roll--it's just not rolling quite as fast as it did last year. Such is the conclusion of Contract Pharma's 2008 outsourcing survey, which found that 52 percent of companies Read more...
Could Clarinex be vulnerable to generics?
Consider this scenario from Fred Hassan's nightmares: The $800 million Clarinex, ostensibly under patent till 2020, Read more...
Zyrtec 'guerilla' flyers spur blog buzz
A new guerilla marketing campaign for over-the-counter Zyrtec proves one thing: If you want attention in the blogosphere, post a few drug ads on telephone poles. They're flyers designed to appear Read more...
FDA probe clears generic Wellbutrin
Listen to all those generics makers heaving sighs of relief. The FDA has given the thumbs-up to Teva's generic Wellbutrin XL, which has been under investigation since early last year. Patients who'd Read more...
FiercePharma passes 20K subscribers
Publisher's Note Last week the FiercePharma newsletter passed the 20,000 subscriber mark. Thousands of more people are reading via the website and RSS feeds, and I want to thank everyone who has Read more...
Caraco to withdraw misshaped metformin
A couple of weeks ago, the Los Angeles Times ran a big package about generic meds. Are they really as good as Read more...
Pfizer might be liable for generic Neurontin
You may pay the fine though you never collected the revenue. That's what a Philadelphia judge told Pfizer and Warner-Lambert last week in a trial over off-label marketing of Neurontin. If the Read more...
SPOTLIGHT: Thais to make their own generics
After announcing that it would bust the patents on four cancer meds, Thailand now says it's building a plant to make local versions of several anti-AIDS meds and the heart drug Clopidogrel. The Read more...
Courts more open to patent-busting
Patents aren't just an issue in Thailand, either. These days, drugmakers are having a more difficult time keeping patent protection on their products, the Financial Times notes. Ever since top U.S. Read more...
Sens. would dispatch pharma anti-reps
Should the feds send out their own pharma reps? Wednesday, the Senate Special Committee on Aging will convene to discuss "academic detailing," which is essentially a straight talk express for pharma. Read more...
| Press ReleasesPRESS RELEASE: CRESTOR ANDA CRESTOR ANDA On 30th October 2007, AstraZeneca received a notice-letter from Cobalt Pharmaceuticals, Inc. (“Cobalt”) notifying AstraZeneca Pharmaceuticals LP, AstraZeneca AB, IPR Pharmaceuticals Read more... PRESS RELEASE: FDA Announces Initiative to Bolster Generic Drug Program FDA Announces Initiative to Bolster Generic Drug Program Effort will streamline generic drug approval process; provide more options for consumers, health professionals The U.S. Food and Drug Read more... PRESS RELEASE: US federal appeals court temporarily stops Teva from selling its generic version of fAMVIR US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir US Court of Appeals for the Federal Circuit issues order prohibiting Teva from Read more... PRESS RELEASE: Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets Teva Receives Favorable Court Decision Regarding Generic Famvir Tablets; Novartis’ Motion for Preliminary Injunction Denied JERUSALEM, Israel--Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) Read more... |
Get more Generics coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight